Type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF)-along with their associated risk factors-have overlapping etiologies, and two or more of these conditions frequently occur in the same patient. Many recent cardiovascular outcome trials (CVOTs) have demonstrated the benefits of agents originally developed to control T2D, ASCVD, or CKD risk factors, and these agents have transcended their primary indications to confer benefits across a range of conditions. This evolution in CVOT evidence calls for practice recommendations that are not constrained by a single discipline to help clinicians manage patients with complex conditions involving diabetes, cardiorenal, and/or metabolic (DCRM) diseases. The ultimate goal for these recommendations is to be comprehensive yet succinct and easy to follow by the nonexpert-whether a specialist or a primary care clinician. To meet this need, we formed a volunteer task force comprising leading cardiologists, nephrologists, endocrinologists, and primary care physicians to develop the DCRM Practice Recommendations, a multispecialty consensus on the comprehensive management of the patient with complicated metabolic disease. The task force recommendations are based on strong evidence and incorporate practical guidance that is clinically relevant and simple to implement, with the aim of improving outcomes in patients with DCRM. The recommendations are presented as 18 separate graphics covering lifestyle therapy, patient self-management education, technology for DCRM management, prediabetes, cognitive dysfunction, vaccinations, clinical tests, lipids, hypertension, anticoagulation and antiplatelet therapy, antihyperglycemic therapy, hypoglycemia, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), ASCVD, HF, CKD, and comorbid HF and CKD, as well as a graphical summary of medications used for DCRM.

Baylor College of Medicine Houston TX USA

Brigham and Women's Hospital Harvard Medical School Boston MA USA

David Geffen School of Medicine UCLA Los Angeles CA USA

Duke University Medical Center Durham NC USA

Emory University Atlanta GA USA

Grunberger Diabetes Institute Bloomfield Hills MI USA Wayne State University School of Medicine Detroit MI USA Oakland University William Beaumont School of Medicine Rochester MI USA Charles University Prague Czech Republic

Johns Hopkins University School of Medicine Baltimore MD USA

Metabolic Institute of America Tarzana CA USA

Mount Sinai School of Medicine New York NY USA

Saint Luke's Mid America Heart Institute University of Missouri Kansas City Kansas City MO USA

Scripps Whittier Institute for Diabetes San Diego CA USA

The Center for Diabetes and Endocrine Care University of Miami Miller School of Medicine Hollywood FL USA

The Frist Clinic Nashville TN USA

Tulane University Health Sciences Center New Orleans LA USA

University of California at Irvine Irvine CA USA

University of California San Diego School of Medicine San Diego CA USA

University of Chicago Medicine Chicago IL USA

University of Colorado Anschutz Medical Campus Denver CO USA

University of Maryland School of Medicine Baltimore MD USA

University of Mississippi Medical Center Jackson MS USA

University of Tennessee Health Science Center Memphis TN USA

University of Texas Health Science Center San Antonio TX USA

University of Washington Seattle WA USA

Vanderbilt University Medical Center Nashville TN USA

Yale School of Medicine New Haven CT USA

000      

00000naa a2200000 a 4500

001      

bmc22011166

003      

CZ-PrNML

005      

20220506130019.0

007      

ta

008      

220425s2022 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.jdiacomp.2021.108101 $2 doi

035    __

$a (PubMed)34922811

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Handelsman, Yehuda $u Metabolic Institute of America, Tarzana, CA, USA. Electronic address: yhandelsman@gmail.com

245    10

$a DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases / $c Y. Handelsman, JE. Anderson, GL. Bakris, CM. Ballantyne, JA. Beckman, DL. Bhatt, ZT. Bloomgarden, B. Bozkurt, MJ. Budoff, J. Butler, S. Dagogo-Jack, IH. de Boer, RA. DeFronzo, RH. Eckel, D. Einhorn, VA. Fonseca, JB. Green, G. Grunberger, C. Guerin, SE. Inzucchi, PS. Jellinger, MN. Kosiborod, P. Kushner, N. Lepor, CW. Mende, ED. Michos, J. Plutzky, PR. Taub, GE. Umpierrez, M. Vaduganathan, MR. Weir

520    9_

$a Type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF)-along with their associated risk factors-have overlapping etiologies, and two or more of these conditions frequently occur in the same patient. Many recent cardiovascular outcome trials (CVOTs) have demonstrated the benefits of agents originally developed to control T2D, ASCVD, or CKD risk factors, and these agents have transcended their primary indications to confer benefits across a range of conditions. This evolution in CVOT evidence calls for practice recommendations that are not constrained by a single discipline to help clinicians manage patients with complex conditions involving diabetes, cardiorenal, and/or metabolic (DCRM) diseases. The ultimate goal for these recommendations is to be comprehensive yet succinct and easy to follow by the nonexpert-whether a specialist or a primary care clinician. To meet this need, we formed a volunteer task force comprising leading cardiologists, nephrologists, endocrinologists, and primary care physicians to develop the DCRM Practice Recommendations, a multispecialty consensus on the comprehensive management of the patient with complicated metabolic disease. The task force recommendations are based on strong evidence and incorporate practical guidance that is clinically relevant and simple to implement, with the aim of improving outcomes in patients with DCRM. The recommendations are presented as 18 separate graphics covering lifestyle therapy, patient self-management education, technology for DCRM management, prediabetes, cognitive dysfunction, vaccinations, clinical tests, lipids, hypertension, anticoagulation and antiplatelet therapy, antihyperglycemic therapy, hypoglycemia, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), ASCVD, HF, CKD, and comorbid HF and CKD, as well as a graphical summary of medications used for DCRM.

650    12

$a kardiovaskulární nemoci $x komplikace $x epidemiologie $x prevence a kontrola $7 D002318

650    12

$a kardiovaskulární systém $7 D002319

650    12

$a diabetes mellitus 2. typu $x komplikace $x epidemiologie $x terapie $7 D003924

650    _2

$a lidé $7 D006801

650    _2

$a hypoglykemika $x terapeutické užití $7 D007004

650    12

$a chronická renální insuficience $x komplikace $x epidemiologie $x terapie $7 D051436

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

655    _2

$a přehledy $7 D016454

700    1_

$a Anderson, John E $u The Frist Clinic, Nashville, TN, USA

700    1_

$a Bakris, George L $u University of Chicago Medicine, Chicago, IL, USA

700    1_

$a Ballantyne, Christie M $u Baylor College of Medicine, Houston, TX, USA

700    1_

$a Beckman, Joshua A $u Vanderbilt University Medical Center, Nashville, TN, USA

700    1_

$a Bhatt, Deepak L $u Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

700    1_

$a Bloomgarden, Zachary T $u Mount Sinai School of Medicine, New York, NY, USA

700    1_

$a Bozkurt, Biykem $u Baylor College of Medicine, Houston, TX, USA

700    1_

$a Budoff, Matthew J $u David Geffen School of Medicine, UCLA, Los Angeles, CA, USA

700    1_

$a Butler, Javed $u University of Mississippi Medical Center, Jackson, MS, USA

700    1_

$a Dagogo-Jack, Samuel $u University of Tennessee Health Science Center, Memphis, TN, USA

700    1_

$a de Boer, Ian H $u University of Washington, Seattle, WA, USA

700    1_

$a DeFronzo, Ralph A $u University of Texas Health Science Center, San Antonio, TX, USA

700    1_

$a Eckel, Robert H $u University of Colorado Anschutz Medical Campus, Denver, CO, USA

700    1_

$a Einhorn, Daniel $u Scripps Whittier Institute for Diabetes, San Diego, CA, USA

700    1_

$a Fonseca, Vivian A $u Tulane University Health Sciences Center, New Orleans, LA, USA

700    1_

$a Green, Jennifer B $u Duke University Medical Center, Durham, NC, USA

700    1_

$a Grunberger, George $u Grunberger Diabetes Institute, Bloomfield Hills, MI, USA, Wayne State University School of Medicine, Detroit, MI, USA, Oakland University William Beaumont School of Medicine, Rochester, MI, USA, Charles University, Prague, Czech Republic

700    1_

$a Guerin, Chris $u University of California San Diego School of Medicine, San Diego, CA, USA

700    1_

$a Inzucchi, Silvio E $u Yale School of Medicine, New Haven, CT, USA

700    1_

$a Jellinger, Paul S $u The Center for Diabetes & Endocrine Care, University of Miami Miller School of Medicine, Hollywood, FL, USA

700    1_

$a Kosiborod, Mikhail N $u Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, MO, USA

700    1_

$a Kushner, Pamela $u University of California at Irvine, Irvine, CA, USA

700    1_

$a Lepor, Norman $u David Geffen School of Medicine, UCLA, Los Angeles, CA, USA

700    1_

$a Mende, Christian W $u University of California San Diego School of Medicine, San Diego, CA, USA

700    1_

$a Michos, Erin D $u Johns Hopkins University School of Medicine, Baltimore, MD, USA

700    1_

$a Plutzky, Jorge $u Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

700    1_

$a Taub, Pam R $u University of California San Diego School of Medicine, San Diego, CA, USA

700    1_

$a Umpierrez, Guillermo E $u Emory University, Atlanta, GA, USA

700    1_

$a Vaduganathan, Muthiah $u Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

700    1_

$a Weir, Matthew R $u University of Maryland School of Medicine, Baltimore, MD, USA

773    0_

$w MED00002638 $t Journal of diabetes and its complications $x 1873-460X $g Roč. 36, č. 2 (2022), s. 108101

856    41

$u https://pubmed.ncbi.nlm.nih.gov/34922811 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20220425 $b ABA008

991    __

$a 20220506130011 $b ABA008

999    __

$a ok $b bmc $g 1788988 $s 1162364

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2022 $b 36 $c 2 $d 108101 $e 20211207 $i 1873-460X $m Journal of diabetes and its complications $n J. Diabetes Complicat. $x MED00002638

LZP    __

$a Pubmed-20220425